NeuroBo reports positive Phase 1 SAD data for DA-1726 obesity drug; no serious AEs

MetaVia Inc.

45 obese participants randomized 6:3 DA-1726 vs placebo; drug safe and well tolerated.
5 AEs in DA-1726 group vs 3 placebo; no serious adverse events reported.
Dose-linear PK observed across investigated range; additional cohorts added to find max tolerated dose.
MAD Part 2 top-line data expected Q1 2025; Part 3 will evaluate early proof of concept.
CEO cites potential best-in-class profile due to balanced GLP1R and glucagon receptor activation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.